Sanofi is nearing a sale of a 50% stake in its consumer unit, valued at 16 billion euros in total, to boost clinical trials ...

Sanofi's Q3 earnings surged, with a 14.4% increase in income to €4.61 billion, led by Dupixent and new launches. Revenue beat ...

Sanofi (SNY) stock gains as company exceeds Q3 earnings estimates with strong vaccine and Dupixent sales, and raises its full ...

PARIS (AP) — PARIS (AP) — Sanofi (SNY) on Friday reported third-quarter earnings of $3.09 billion. The company said it had net income of $1.23 per share. Earnings, adjusted for non-recurring costs, ...

Sanofi said this morning that its pipeline includes ... build-up to an R&D presentation to investors that will be held in New York later today, and also after the France-headquartered group ...

Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice ...

Sanofi is deepening its commitment to targeted radiation treatments for cancer with a €300 million equity investment in a new entity pursuing next-generation radioligand therapies. The new ...

Sanofi has returned with 300 million euros ($326 million) to set up a more permanent radioligand project. The new entity, which will operate under the Orano Med brand, will be focused on ...

Sanofi is now in “exclusive negotiations ... With the French government saying that it has received assurances from New York City-based CD&R that it will keep Opella’s manufacturing facilities ...

(Bloomberg) -- GSK Plc, Sanofi and CSL Ltd. secured $72 million ... For a Master of Brutalist Provocations, a Modest Museum Appraisal Mexico City Restricts Airbnb Rentals to Curb ‘Gentrification ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail the deal ...